Intradermal vs intramuscular vaccine against hepatitis B infection in dialysis patients: A meta-analysis of randomized trials

Journal of Viral Hepatitis

Volumn 18, Issue 10, 2011, Pages 730-737

  Fabrizi, F ^a,b   Dixit, V ^b   Messa, P ^a   Martin, P ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

dialysis; intradermal hepatitis B virus vaccine; meta analysis; randomized trials

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

ANTIBODY DETECTION; ARTICLE; CHRONIC KIDNEY FAILURE; DIALYSIS; DRUG DOSAGE FORM COMPARISON; ENZYME IMMUNOASSAY; FEVER; FOLLOW UP; HEMODIALYSIS PATIENT; HEPATITIS B; HUMAN; INFECTION RISK; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; SEROCONVERSION; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; VACCINATION;

ADULT; AGED; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; RENAL DIALYSIS; VACCINATION;

EID: 80052828203     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01354.x     Document Type: Article

References (41)

1. Centers for Disease Control. Recommendations for preventing transmission of infection among chronic haemodialysis patients. MMWR Recomm Rep 2001; 50: 1-43.
2. Rangel MC, Coronado VG, Euler GL, Strikas RA, for the Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Vaccine recommendations for patients on chronic dialysis. Semin Dial 2002; 13: 101-107.
3. Sangare L, Manhart L, Zehrung D, Wang CC,. Intradermal hepatitis B vaccination: a systematic review and meta-analysis. Vaccine 2009; 27: 1777-1786.
4. Fabrizi F, Dixit V, Magnini M, Elli A, Martin P,. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 2006; 24: 497-506. (Pubitemid 44051325)
5. Poynard T, Conn HO,. The retrieval of randomised clinical trials in liver diseases from the medical literature: a comparison of MEDLARS and manual methods. Control Clin Trials 1985; 6: 271-279. (Pubitemid 16173553)
6. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1985; 6: 271-279.
7. Petitti DB,. Approaches to heterogeneity in meta-analysis. Stat Med 2001; 20: 3625-3633. (Pubitemid 33114432)
8. Higgins JPT, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560. (Pubitemid 37088507)
9. Galbraith RF,. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988; 7: 889-894.
10. Klein S, Simes J, Blackburn GL,. Total parenteral nutrition and cancer clinical trial. Cancer 1986; 58: 1378-1386. (Pubitemid 16053158)
11. Sorkhi H, Dooki MR, Ebrahimnejad MS,. Low dose intradermal and subcutaneous versus intramuscular hepatitis B vaccination in primary non-responding hemodialysis patients. J Med Assoc Thai 2006; 89: 1648-1653. (Pubitemid 44747535)
12. Chang PC, Schrander-van der Meer AM, van Dorp WT, van Leer E,. Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol Dial Transplant 1996; 11: 191-193. (Pubitemid 26038488)
13. Mettang T, Schenk U, Thomas S, et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study. Nephron 1996; 72: 192-196.
14. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F,. Intradermal vs. Intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12: 1204-1211. (Pubitemid 27230558)
15. Propst T, Propst A, Lhotta K, Vogel W, Konig P,. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32: 1041-1045. (Pubitemid 28551169)
16. Vincent L, John GT, Abraham P, Jacob CK,. An intradermal vaccine protocol against hepatitis B in a haemodialysis population. Natl Med J India 1998; 11: 48-50.
17. Charest AF, McDougall J, Goldstein MB,. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 976-982.
18. Chau KF, Cheng YL, Tsang DN, et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis 2004; 43: 910-917. (Pubitemid 38529629)
19. Roozbeh J, Moini M, Lankarani KB, Sagheb MM, Shahpoori S, Bastani B,. Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysis. ASAIO J 2005; 51: 242-245. (Pubitemid 40677133)
20. Argani H, Akhtarishojaie E,. Levamizole enhances immune responsiveness to intradermal and intramuscular hepatitis B vaccination in chronic hemodialysis patients. J Immune Based Ther 2006; 4: 1-5.
21. Karahocagil KM, Buzgan T, Irmak H, Karsen H, Akdeniz H,. Comparison of intramuscular and intradermal application of hepatitis B vaccine in hemodialysis patients. Ren Fail 2006; 28: 561-565. (Pubitemid 44581937)
22. Argani H, Akhtarishojaie E,. Levamizole enhances immune responsiveness to intradermal and intramuscular hepatitis B vaccination in chronic hemodialysis patients. J Immune Based Ther Vaccines 2006; 4: 3.
23. Micozkadioglu H, Zumrutdal A, Torun D, Sezer S, Ozdemir FN,. Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. Ren Fail 2007; 29: 285-288. (Pubitemid 46752340)
24. Barraclough KA, Wiggins KJ, Hawley CM, et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis 2009; 54: 95-103.
25. Fabrizi F, Di Filippo S, Marcelli D, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients: long-term evaluation and cost-effectiveness analysis. Nephron 1996; 72: 536-543.
26. Tong NK, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvant hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68: 2298-2303. (Pubitemid 43117807)
27. Surquin M, Tielemans CL, Kulcsar I, et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02-adjuvanted hepatitis B vaccine. Kidney Int 2010; 77: 247-255.
28. Miquilena-Colina ME, Lozano-Rodriguez T, Garcia-Pozo L, et al. Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Vaccine 2009; 54: 5654-5660.
29. Donati D, Gastaldi L,. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 1998; 50: 133-136.
30. Kapoor D, Agarwal SR, Singh NP, Thakur V, Sarin SK,. Granulocyte- macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat 1999; 6: 405-409. (Pubitemid 29470171)
31. Alavian SM, Tabatabaei SV,. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther 2010; 32: 1-10.
32. DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003; 42: 1184-1192. (Pubitemid 37486762)
33. Ono K, Kahiwagi S,. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients. Nephron 1991; 58: 47-51.
34. Marangi AL, Giordano R, Montanaro A, De Padova F, Schiavone MG, Basile C,. A successful two-step integrated protocol of anti-HBV vaccination in chronic uremia. Nephron 1992; 61: 331-332.
35. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355: 561-565.
36. Liu Y, Kendall MA,. Optimization of a jet-propelled particle injection system for the uniform transdermal delivery of drug/vaccine. Biotechnol Bioeng 2007; 97: 1300-1308. (Pubitemid 47195324)
37. Raviprakash K, Porter KR,. Needle-free injection of DNA vaccines: a brief overview and methodology. Methods Mol Med 2006; 127: 83-89.
38. Wu T, Li Y, Bian Z, Liu G, Moher D,. Randomized trials published in some Chinese journals: how many are randomized? Trials 2009; 10: 46.
39. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-613. (Pubitemid 28380142)
40. Moher D, Schulz KF, Altman D,. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285: 1987-1991. (Pubitemid 32366951)
41. Miller ER, Alter MJ, Tokars JL,. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999; 33: 356-360. (Pubitemid 29072240)